Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1613-mCRC, Adv/Met, TP vs CETIRI | 1 | Y | 0 Screening | 130 | 218 | 39 | 25 | 13 | 3 | 1 | 11/27/2017 | 292 | 115 |
| 218 | 39 | 25 | 13 | 3 | 1 | |||||||||
| 2 | Y | 1 Trastuzumab + Pertuzumab | 130 | 21 | 6 | 6 | 3 | 2 | 0 | 11/27/2017 | ||||
| 2 Cetuximab + Irinotecan | 24 | 6 | 5 | 5 | 1 | 0 | ||||||||
| 45 | 12 | 11 | 8 | 3 | 0 | |||||||||
| 3 | Y | 3 Crossover: Trastuz + Pertuz | 130 | 13 | 2 | 1 | 1 | 1 | 0 | 11/27/2017 | ||||
| 13 | 2 | 1 | 1 | 1 | 0 | |||||||||
| S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | 1 | Y | 1 Ramucirumab + Paclitaxel | 94 | 4 | 4 | 4 | 0 | 0 | 0 | 06/01/2020 | 148 | 54 | |
| 2 FOLFIRI | 4 | 4 | 2 | 1 | 0 | 0 | ||||||||
| 8 | 8 | 6 | 1 | 0 | 0 | |||||||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | 1 | Y | 1 Olaparib + Pembrolizumab | 88 | 1 | 1 | 1 | 1 | 0 | 0 | 02/22/2021 | 72 | 36 | |
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| Yes | A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC | 1 | E | Total Registrations | 44 | 18 | 12 | 3 | 0 | 0 | 03/23/2018 | 354 | 179 | |
| 44 | 18 | 12 | 3 | 0 | 0 | |||||||||
| A021806-Pancreas, Perioperative vs Adjuvant Chemo | 0 | E | Total Registrations | 4 | 4 | 3 | 2 | 0 | 0 | 10/08/2020 | 206 | 104 | ||
| 4 | 4 | 3 | 2 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 3 | 3 | 3 | 1 | 0 | 0 | 10/08/2020 | |||||
| 3 | 3 | 3 | 1 | 0 | 0 | |||||||||
| EA2186-PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI | 1 | E | Total Registrations | 6 | 6 | 6 | 3 | 1 | 0 | 11/18/2020 | 19 | 18 | ||
| 6 | 6 | 6 | 3 | 1 | 0 | |||||||||
| No | A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo | 1 | E | Total Registrations | 10 | 4 | 2 | 0 | 0 | 0 | 06/11/2019 | 241 | 96 | |
| 10 | 4 | 2 | 0 | 0 | 0 | |||||||||
| A021703-COLON, Adv/Met, Chemo + Std v High dose V-D3 | 1 | E | Total Registrations | 9 | 7 | 5 | 2 | 0 | 0 | 03/04/2020 | 268 | 144 | ||
| 9 | 7 | 5 | 2 | 0 | 0 | |||||||||
| EA2142-GI NEC, Adv G3, EP vs TMZ + CAP | 1 | E | Total Registrations | 6 | 1 | 1 | 0 | 0 | 0 | 07/14/2016 | 169 | 89 | ||
| 6 | 1 | 1 | 0 | 0 | 0 | |||||||||
| EA2165-Anal, Stg II-III, Nivolumab after CMT | 1 | E | Total Registrations | 29 | 9 | 5 | 1 | 0 | 0 | 10/09/2018 | 274 | 138 | ||
| 29 | 9 | 5 | 1 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 24 | 9 | 5 | 1 | 0 | 0 | 10/09/2018 | |||||
| 24 | 9 | 5 | 1 | 0 | 0 | |||||||||
| EA2187-ICC, Carboplatin+Paclitaxel +/- Pevonedistat | 1 | E | Total Registrations | 7 | 7 | 7 | 5 | 3 | 0 | 12/09/2020 | 25 | 9 | ||
| 7 | 7 | 7 | 5 | 3 | 0 | |||||||||
| NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy | 1 | T | Total Registrations | 14 | 1 | 0 | 0 | 0 | 0 | 04/18/2018 | 273 | 126 | ||
| 14 | 1 | 0 | 0 | 0 | 0 | |||||||||
| NRGGI005-COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy | 1 | T | Total Registrations | 3 | 3 | 1 | 0 | 0 | 0 | 07/06/2020 | 336 | 146 | ||
| 3 | 3 | 1 | 0 | 0 | 0 | |||||||||